Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
December 24, 2001
- Sanko Junyaku: Microplate EIA System
December 24, 2001
- Tanabe to Continue Strategic Technical Alliances with Foreign Companies
December 24, 2001
- Sysmex Develops Hemocytometer for POC Use
December 24, 2001
- 33 JPMA Member Companies: Sales Up 2.4%, Profits Up 56.5%
December 24, 2001
- Pharmacia to Spin Off Stake in Monsanto
December 24, 2001
- WORLD NEWS I N BRIEF
December 17, 2001
- Basic Policy for FY2002 Budget Approved
December 17, 2001
- 1st Large Epidemiologic Study on Arteriosclerotic Disease to Start in Japan
December 17, 2001
- Medical Fees to Be Reduced: The Question Is How Much
December 17, 2001
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
December 17, 2001
- Domestic Drug Production Down 1.7% to \6,18 Trillion in FY2000
December 17, 2001
- DIAGNOSTIC NEWS IN BRIEF
December 17, 2001
- 17th Quality Reevaluation to Start on 18 Mono-drugs, 8 Combinations
December 17, 2001
- Sephora to Withdraw from Japan
December 17, 2001
- Quality Reevaluation Completed for Drugs Accounting for 60% of Total Market
December 17, 2001
- Matsumotokiyoshi: Sales, Net Profits Increase 11%, 46.1%, Respectively
December 17, 2001
- REGULATORY NEWS IN BRIEF
December 17, 2001
- Kraft: Dispensing Business Boosts Sales by 16.8%
December 17, 2001
- FTC Issues Recommendation to 9 Wholesalers in the Tohoku Region
December 17, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…